U.S., European Courts Deal Another Blow to AstraZeneca's Ulcer Drug

Law360, New York (December 11, 2003, 12:00 AM EST) -- Courts in Europe and the U.S. dealt further setbacks for AstraZeneca’s efforts to extend patent rights to an ulcer treatment that was once the world’s best-selling drug.

A three-judge panel of the United States Court of Appeals upheld the right of SchwarzPharma AG to sell cheaper versions of Prilosec (known as Losec in Europe), but upheld AstraZeneca's patents and affirmed that Andrx, Genpharm and Cheminor infringed them.

Meanwhile, the Luxembourg-based European Court of Justice ruled against the European drug maker’s bid to extend a European patent...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.